324 related articles for article (PubMed ID: 29212804)
1. Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J; Green AR
Blood; 2017 Dec; 130(23):2475-2483. PubMed ID: 29212804
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J; Green AR
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):470-479. PubMed ID: 29222295
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
[TBL] [Abstract][Full Text] [Related]
4. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
Maslah N; Benajiba L; Giraudier S; Kiladjian JJ; Cassinat B
Leukemia; 2023 May; 37(5):957-963. PubMed ID: 37002477
[TBL] [Abstract][Full Text] [Related]
5. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.
Hobbs GS; Hanasoge Somasundara AV; Kleppe M; Litvin R; Arcila M; Ahn J; McKenney AS; Knapp K; Ptashkin R; Weinstein H; Heinemann MH; Francis J; Chanel S; Berman E; Mauro M; Tallman MS; Heaney ML; Levine RL; Rampal RK
Haematologica; 2018 Jan; 103(1):e5-e9. PubMed ID: 29051283
[No Abstract] [Full Text] [Related]
7. Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies.
Belver L; Ferrando AA
Cancer Discov; 2015 Mar; 5(3):234-6. PubMed ID: 25749974
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Cancer Discov; ; . PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
